{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:32:57Z","timestamp":1783366377175,"version":"3.54.6"},"reference-count":58,"publisher":"Societatea Romana de Morfologie","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rom J Morphol Embryol"],"published-print":{"date-parts":[[2025,5,23]]},"abstract":"<jats:p>Background: Serrated colorectal lesions represent a potential precursor of 15\u201330% of colorectal carcinoma, although the exact mechanisms are not fully understood. The serrated pathway of colorectal carcinogenesis may be correlated with gastric-type metaplasia of the colon and modified expression of caudal type homeobox 2 (CDX2) and local mucins (MUCs). Patients, Materials and Methods: We performed a retrospective study of patients with resected polyps during 2014\u20132021. The prevalence of serrated lesions, risk factors associated with malignant polyps, and the role of gastric-type metaplasia associated with serrated pathway of carcinogenesis (CDX2, MUC5AC) and of p53 immunostaining in serrated lesions with dysplasia and carcinoma were assessed. Results: Five hundred twenty two (522) patients had 1199 polyps removed. We noted a 12.8% prevalence of sessile serrated adenoma\/polyps (SSA\/P) and traditional serrated adenomas (TSA); 17.4% had hyperplastic polyps. The malignancy rate of resected polyps was higher in tubulovillous adenoma (TVA) and villous adenoma (12.3\u201320%) than in SSA\/P (8.3%) and TSA (4.8%). In TSA, no significant associations between malignancy and age, gender, size, location, or endoscopic appearance were noted. In SSA\/P, malignant polyps were much larger, especially for the right side lesions, but the macroscopic type was not correlated with malignancy risk. Immunohistochemistry (IHC) was performed in 26 polyps with dysplasia or carcinoma; all cases had CDX2 immunostaining in the tumor cell\u2019s nucleus, with an average percentage of 96.5%. MUC5AC immunostaining was identified in the tumor cells\u2019 cytoplasm, with an average percentage of 31.81%; the intensity reaction was variable (average score 4.5). The percentage, intensity, and score for CDX2 IHC were similar for TSA and TVA and were lower for SSA\/P with low-grade dysplasia (LGD), while for SSA\/P with high-grade dysplasia (HGD) or carcinoma in situ (CIS), the percentage, intensity, and score were similar to TSA and TVA. p53 immunostaining was also positive in all cases, with an average percentage of 50.95% in the tumor cells\u2019 nucleus. p53 and MUC5AC had increased percentage, intensity, and scores from LGD to HGD in SSA\/P and decreased mean percentage, intensity, and scores in TSA and TVA. Conclusions: The risk of malignancy in serrated lesions seems lower than in conventional adenomas, however, sessile serrated lesions can be involved in the appearance of interval cancers because of flat and pale macroscopic aspects. Gastric-type intestinal metaplasia may be associated with the serrated pathway, but more studies are needed to clarify mechanisms associated with serrated carcinogenesis.<\/jats:p>","DOI":"10.47162\/rjme.66.1.09","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T08:40:16Z","timestamp":1748594416000},"page":"99-109","source":"Crossref","is-referenced-by-count":2,"title":["The role of CDX2, MUC5AC, and p53 in the evaluation of the progression of serrated lesions toward colorectal carcinoma"],"prefix":"10.47162","volume":"66","author":[{"name":"Department of Gastroenterology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiu Marian","family":"Cazacu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevasti\u0163a","family":"Iordache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Gastroenterology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad Florin","family":"Iov\u0103nescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Gastroenterology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Streba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Oncology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Daniela","family":"Neagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Jana","family":"Busuioc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Histology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"C\u00e2r\u0163u","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Surgery, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirela Marinela","family":"Florescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Pathology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26736","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"\"[1] De Palma FDE, D'Argenio V, Pol J, Kroemer G, Maiuri MC, Salvatore F. The molecular hallmarks of the serrated pathway in colorectal cancer. Cancers (Basel), 2019, 11(7):1017. https:\/\/doi.org\/10.3390\/cancers11071017","DOI":"10.3390\/cancers11071017"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"[2] Sakai E, Fukuyo M, Ohata K, Matsusaka K, Doi N, Mano Y, Takane K, Abe H, Yagi K, Matsuhashi N, Fukushima J, Fukayama M, Akagi K, Aburatani H, Nakajima A, Kaneda A. Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway. Int J Cancer, 2016, 138(7):1634-1644. https:\/\/doi.org\/10.1002\/ijc.29903","DOI":"10.1002\/ijc.29903"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"[3] Fu X, Yang X, Chen K, Zhang Y. Retained cell-cell adhesion in serrated neoplastic pathway as opposed to conventional colorectal adenomas. J Histochem Cytochem, 2011, 59(2):158-166. https:\/\/doi.org\/10.1369\/jhc.2010.956722","DOI":"10.1369\/jhc.2010.956722"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"[4] Gupta V, East JE. Optimal endoscopic treatment and surveillance of serrated polyps. Gut Liver, 2020, 14(4):423-429. https:\/\/doi.org\/10.5009\/gnl19202","DOI":"10.5009\/gnl19202"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"[5] Herreros de Tejada A, Gonz\u00e1lez-Lois C, Santiago J. Serrated lesions and serrated polyposis syndrome. Rev Esp Enferm Dig, 2017, 109(7):516-526. https:\/\/doi.org\/10.17235\/reed.2017.4065\/2015","DOI":"10.17235\/reed.2017.4065\/2015"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"[6] Bettington ML, Walker NI, Rosty C, Brown IS, Clouston AD, McKeone DM, Pearson SA, Klein K, Leggett BA, Whitehall VL. A clinicopathological and molecular analysis of 200 traditional serrated adenomas. Mod Pathol, 2015, 28(3):414-427. https:\/\/doi.org\/10.1038\/modpathol.2014.122","DOI":"10.1038\/modpathol.2014.122"},{"key":"ref6","unstructured":"[7] Pap Z, P\u00e1vai Z, D\u00e9nes L, Br\u00eenzaniuc K, Jung I. Hyperplastic polyps and serrated adenomas: precancerous lesions with mixed immunophenotype. Rom J Morphol Embryol, 2011, 52(3):797-802."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"[8] Xu S, Wang L, Yang G, Li L, Wang J, Xu C, Ge C. Clinicopathological observations of colorectal serrated lesions associated with invasive carcinoma and high-grade intraepithelial neoplasm. Exp Ther Med, 2013, 6(5):1113-1120. https:\/\/doi.org\/10.3892\/etm.2013.1270","DOI":"10.3892\/etm.2013.1270"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"[9] Sweetser S, Smyrk TC, Sinicrope FA. Serrated colon polyps as precursors to colorectal cancer. Clin Gastroenterol Hepatol, 2013, 11(7):760-767; quiz e54-e55. https:\/\/doi.org\/10.1016\/j.cgh.2012.12.004","DOI":"10.1016\/j.cgh.2012.12.004"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"[10] Anderson JC. Pathogenesis and management of serrated polyps: current status and future directions. Gut Liver, 2014, 8(6):582-589. https:\/\/doi.org\/10.5009\/gnl14248","DOI":"10.5009\/gnl14248"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"[11] Ng SC, Ching JYL, Chan VCW, Wong MCS, Tang R, Wong S, Luk AKC, Lam TYT, Gao Q, Chan AWH, Wu JCY, Chan FKL, Lau JYW, Sung JJY. Association between serrated polyps and the risk of synchronous advanced colorectal neoplasia in average-risk individuals. Aliment Pharmacol Ther, 2015, 41(1):108-115. https:\/\/doi.org\/10.1111\/apt.13003","DOI":"10.1111\/apt.13003"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"[12] Sakamoto N, Feng Y, Stolfi C, Kurosu Y, Green M, Lin J, Green ME, Sentani K, Yasui W, McMahon M, Hardiman KM, Spence JR, Horita N, Greenson JK, Kuick R, Cho KR, Fearon ER. BRAFV600E cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis. Elife, 2017, 6:e20331. https:\/\/doi.org\/10.7554\/eLife.20331","DOI":"10.7554\/eLife.20331"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"[13] Yachida S, Mudali S, Martin SA, Montgomery EA, Iacobuzio-Donahue CA. Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. Am J Surg Pathol, 2009, 33(12):1823-1832. https:\/\/doi.org\/10.1097\/PAS.0b013e3181b6da19","DOI":"10.1097\/PAS.0b013e3181b6da19"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"[14] Hirano D, Urabe Y, Tanaka S, Nakamura K, Ninomiya Y, Yuge R, Hayashi R, Oka S, Kitadai Y, Shimamoto F, Arihiro K, Chayama K. Early-stage serrated adenocarcinomas are divided into several molecularly distinct subtypes. PLoS One, 2019, 14(2):e0211477. https:\/\/doi.org\/10.1371\/journal.pone.0211477","DOI":"10.1371\/journal.pone.0211477"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"[15] Saiki H, Nishida T, Yamamoto M, Hayashi S, Shimakoshi H, Shimoda A, Amano T, Sakamoto A, Otake Y, Sugimoto A, Takahashi K, Mukai K, Matsubara T, Nakajima S, Fukui K, Inada M, Yamamoto K, Tokuda R, Adachi S. Frequency of coexistent carcinoma in sessile serrated adenoma\/polyps and traditional serrated adenomas removed by endoscopic resection. Endosc Int Open, 2016, 4(4):E451-E458. https:\/\/doi.org\/10.1055\/s-0042-103239","DOI":"10.1055\/s-0042-103239"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"[16] Haque TR, Bradshaw PT, Crockett SD. Risk factors for serrated polyps of the colorectum. Dig Dis Sci, 2014, 59(12):2874-2889. https:\/\/doi.org\/10.1007\/s10620-014-3277-1","DOI":"10.1007\/s10620-014-3277-1"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"[17] Murakami T, Akazawa Y, Yatagai N, Hiromoto T, Sasahara N, Saito T, Sakamoto N, Nagahara A, Yao T. Molecular characterization of sessile serrated adenoma\/polyps with dysplasia\/carcinoma based on immunohistochemistry, next-generation sequencing, and microsatellite instability testing: a case series study. Diagn Pathol, 2018, 13(1):88. https:\/\/doi.org\/10.1186\/s13000-018-0771-3","DOI":"10.1186\/s13000-018-0771-3"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"[18] Fennell LJ, Jamieson S, McKeone D, Corish T, Rohdmann M, Furner T, Bettington M, Liu C, Kawamata F, Bond C, Van De Pols J, Leggett B, Whitehall V. MLH1-93 G\/a polymorphism is associated with MLH1 promoter methylation and protein loss in dysplastic sessile serrated adenomas with BRAFV600E mutation. BMC Cancer, 2018, 18(1):35. https:\/\/doi.org\/10.1186\/s12885-017-3946-5","DOI":"10.1186\/s12885-017-3946-5"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"[19] Dhir M, Yachida S, Van Neste L, Gl\u00f6ckner SC, Jeschke J, Pappou EP, Montgomery EA, Herman JG, Baylin SB, Iacobuzio-Donahue C, Ahuja N. Sessile serrated adenomas and classical adenomas: an epigenetic perspective on premalignant neoplastic lesions of the gastrointestinal tract. Int J Cancer, 2011, 129(8):1889-1898. https:\/\/doi.org\/10.1002\/ijc.25847","DOI":"10.1002\/ijc.25847"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"[20] Tsai JH, Liau JY, Lin YL, Lin LI, Cheng YC, Cheng ML, Jeng YM. Traditional serrated adenoma has two pathways of neoplastic progression that are distinct from the sessile serrated pathway of colorectal carcinogenesis. Mod Pathol, 2014, 27(10):1375-1385. https:\/\/doi.org\/10.1038\/modpathol.2014.35","DOI":"10.1038\/modpathol.2014.35"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"[21] Balbinot C, Armant O, Elarouci N, Marisa L, Martin E, De Clara E, Onea A, Deschamps J, Beck F, Freund JN, Duluc I. The Cdx2 homeobox gene suppresses intestinal tumorigenesis through non-cell-autonomous mechanisms. J Exp Med, 2018, 215(3):911-926. https:\/\/doi.org\/10.1084\/jem.20170934","DOI":"10.1084\/jem.20170934"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"[22] Yu J, Liu D, Sun X, Yang K, Yao J, Cheng C, Wang C, Zheng J. CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt\/\u03b2-catenin signaling via transactivation of GSK-3\u03b2 and Axin2 expression. Cell Death Dis, 2019, 10(1):26. https:\/\/doi.org\/10.1038\/s41419-018-1263-9","DOI":"10.1038\/s41419-018-1263-9"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"[23] Rosty C, Hewett DG, Brown IS, Leggett BA, Whitehall VLJ. Serrated polyps of the large intestine: current understanding of diagnosis, pathogenesis, and clinical management. J Gastroenterol, 2013, 48(3):287-302. https:\/\/doi.org\/10.1007\/s00535-012-0720-y","DOI":"10.1007\/s00535-012-0720-y"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"[24] Chawengsaksophak K. Cdx2 animal models reveal developmental origins of cancers. Genes (Basel), 2019, 10(11):928. https:\/\/doi.org\/10.3390\/genes10110928","DOI":"10.3390\/genes10110928"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"[25] Walsh MD, Clendenning M, Williamson E, Pearson SA, Walters RJ, Nagler B, Packenas D, Win AK, Hopper JL, Jenkins MA, Haydon AM, Rosty C, English DR, Giles GG, McGuckin MA, Young JP, Buchanan DD. Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Mod Pathol, 2013, 26(12):1642-1656. https:\/\/doi.org\/10.1038\/modpathol.2013.101","DOI":"10.1038\/modpathol.2013.101"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"[26] Khaidakov M, Lai KK, Roudachevski D, Sargsyan J, Goyne HE, Pai RK, Lamps LW, Hagedorn CH. Gastric proteins MUC5AC and TFF1 as potential diagnostic markers of colonic sessile serrated adenomas\/polyps. Am J Clin Pathol, 2016, 146(5):530-537. https:\/\/doi.org\/10.1093\/ajcp\/aqw142","DOI":"10.1093\/ajcp\/aqw142"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"[27] Tsai JH, Lin YL, Cheng YC, Chen CC, Lin LI, Tseng LH, Cheng ML, Liau JY, Jeng YM. Aberrant expression of annexin A10 is closely related to gastric phenotype in serrated pathway to colorectal carcinoma. Mod Pathol, 2015, 28(2):268-278. https:\/\/doi.org\/10.1038\/modpathol.2014.96","DOI":"10.1038\/modpathol.2014.96"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"[28] Nussrat FL, Ali HH, Hussein HG, Al-Ukashi RJ. Immunohistochemical expression of Ki-67 and p53 in colorectal adenomas: a clinicopathological study. Oman Med J, 2011, 26(4):229-234. https:\/\/doi.org\/10.5001\/omj.2011.57","DOI":"10.5001\/omj.2011.57"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"[29] Fujita K, Yamamoto H, Matsumoto T, Hirahashi M, Gushima M, Kishimoto J, Nishiyama K, Taguchi T, Yao T, Oda Y. Sessile serrated adenoma with early neoplastic progression: a clinicopathologic and molecular study. Am J Surg Pathol, 2011, 35(2):295-304. https:\/\/doi.org\/10.1097\/PAS.0b013e318205df36","DOI":"10.1097\/PAS.0b013e318205df36"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"[30] Fu B, Yachida S, Morgan R, Zhong Y, Montgomery EA, Iacobuzio-Donahue CA. Clinicopathologic and genetic characterization of traditional serrated adenomas of the colon. Am J Clin Pathol, 2012, 138(3):356-366. https:\/\/doi.org\/10.1309\/AJCPVT7LC4CRPZSK","DOI":"10.1309\/AJCPVT7LC4CRPZSK"},{"key":"ref30","unstructured":"[31] Pap Z, Ily\u00e9s I\u00c1, Mocan SL, D\u00e9nes L, Muic\u0103 Nagy-Bota MC, P\u00e1vai Z, Sz\u00e1nt\u00f3 A. Changes in immunoexpression of p53, Ki-67, Ets-1, APAF-1 and PTEN in serrated and conventional colon adenomas. Rom J Morphol Embryol, 2015, 56(4):1389-1396."},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"[32] Cazacu SM, S\u0103ftoiu A, Iordache S, Ghilu\u015fi MC, Georgescu CV, Iov\u0103nescu VF, Neagoe CD, Streba L, Cali\u0163a M, Burtea ED, C\u00e2r\u0163u D, Leru PM. Factors predicting occurrence and therapeutic choice in malignant colorectal polyps: a study of 13 years of colonoscopic polypectomy. Rom J Morphol Embryol, 2021, 62(4):917-928. https:\/\/doi.org\/10.47162\/RJME.62.4.04","DOI":"10.47162\/RJME.62.4.04"},{"key":"ref32","unstructured":"[33] Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). World Health Organization (WHO) Classification of tumours of the digestive system. 4th edition, vol. 3, International Agency for Research on Cancer (IARC) Press, Lyon, France, 2010."},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"[34] Sugai T, Eizuka M, Fujita Y, Kawasaki K, Yamamoto E, Ishida K, Yamano H, Suzuki H, Matsumoto T. Molecular profiling based on KRAS\/BRAF mutation, methylation, and microsatellite statuses in serrated lesions. Dig Dis Sci, 2018, 63(10):2626-2638. https:\/\/doi.org\/10.1007\/s10620-018-5167-4","DOI":"10.1007\/s10620-018-5167-4"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"[35] Fidalgo C, Santos L, Rosa I, Fonseca R, Lage P, Claro I, Chaves P, Dias Pereira A. Hyperplastic polyp? Look again... the impact of the new classification for serrated polyps. Acta Med Port, 2014, 27(3):304-308. https:\/\/doi.org\/10.20344\/amp.4725","DOI":"10.20344\/amp.4725"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"[36] Cao HL, Chen X, Du SC, Song WJ, Wang WQ, Xu MQ, Wang SN, Piao MY, Cao XC, Wang BM. Detection rate, distribution, clinical and pathological features of colorectal serrated polyps. Chin Med J (Engl), 2016, 129(20):2427-2433. https:\/\/doi.org\/10.4103\/0366-6999.191759","DOI":"10.4103\/0366-6999.191759"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"[37] Erhardt JG, Kreichgauer HP, Meisner C, Bode JC, Bode C. Alcohol, cigarette smoking, dietary factors and the risk of colorectal adenomas and hyperplastic polyps - a case control study. Eur J Nutr, 2002, 41(1):35-43. https:\/\/doi.org\/10.1007\/s003940200004","DOI":"10.1007\/s003940200004"},{"key":"ref37","unstructured":"[38] Morimoto LM, Newcomb PA, Ulrich CM, Bostick RM, Lais CJ, Potter JD. Risk factors for hyperplastic and adenomatous polyps: evidence for malignant potential? Cancer Epidemiol Biomarkers Prev, 2002, 11(10 Pt 1):1012-1018."},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"[39] Bouwens MWE, Winkens B, Rondagh EJA, Driessen AL, Riedl RG, Masclee AAM, Sanduleanu S. Simple clinical risk score identifies patients with serrated polyps in routine practice. Cancer Prev Res (Phila), 2013, 6(8):855-863. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-13-0022","DOI":"10.1158\/1940-6207.CAPR-13-0022"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"[40] Wallace K, Grau MV, Ahnen D, Snover DC, Robertson DJ, Mahnke D, Gui J, Barry EL, Summers RW, McKeown-Eyssen G, Haile RW, Baron JA. The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum. Cancer Epidemiol Biomarkers Prev, 2009, 18(8):2310-2317. https:\/\/doi.org\/10.1158\/1055-9965.EPI-09-0211","DOI":"10.1158\/1055-9965.EPI-09-0211"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"[41] Min YW, Lee JH, Lee SH, Park DI, Han DS, Rhee PL, Kim JJ, Rhee JC, Kim YH. Prevalence of proximal colon serrated polyps in a population at average risk undergoing screening colonoscopy: a multicenter study. Clin Res Hepatol Gastroenterol, 2012, 36(6):604-608. https:\/\/doi.org\/10.1016\/j.clinre.2011.12.016","DOI":"10.1016\/j.clinre.2011.12.016"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"[42] Lash RH, Genta RM, Schuler CM. Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients. J Clin Pathol, 2010, 63(8):681-686. https:\/\/doi.org\/10.1136\/jcp.2010.075507","DOI":"10.1136\/jcp.2010.075507"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"[43] Carr NJ, Mahajan H, Tan KL, Hawkins NJ, Ward RL. Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma. J Clin Pathol, 2009, 62(6):516-518. https:\/\/doi.org\/10.1136\/jcp.2008.061960","DOI":"10.1136\/jcp.2008.061960"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"[44] Spring KJ, Zhao ZZ, Karamatic R, Walsh MD, Whitehall VL, Pike T, Simms LA, Young J, James M, Montgomery GW, Appleyard M, Hewett D, Togashi K, Jass JR, Leggett BA. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology, 2006, 131(5):1400-1407. https:\/\/doi.org\/10.1053\/j.gastro.2006.08.038","DOI":"10.1053\/j.gastro.2006.08.038"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"[45] Hisamatsu K, Noguchi K, Tomita H, Muto A, Yamada N, Kobayashi K, Hirata A, Kanayama T, Niwa A, Ishida K, Nakashima T, Hatano Y, Suzui N, Miyazaki T, Hara A. Distinctive crypt shape in a sessile serrated adenoma\/polyp: distribution of Ki67-, p16INK4a-, WNT5A-positive cells and intraepithelial lymphocytes. Oncol Rep, 2017, 38(2):775-784. https:\/\/doi.org\/10.3892\/or.2017.5725","DOI":"10.3892\/or.2017.5725"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"[46] Anderson JC, Rangasamy P, Rustagi T, Myers M, Sanders M, Vaziri H, Wu G, Birk JW, Protiva P. Risk factors for sessile serrated adenomas. J Clin Gastroenterol, 2011, 45(8):694-699. https:\/\/doi.org\/10.1097\/MCG.0b013e318207f3cf","DOI":"10.1097\/MCG.0b013e318207f3cf"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"[47] Ohki D, Yamamichi N, Sakaguchi Y, Takahashi Y, Kageyama-Yahara N, Yamamichi M, Takeuchi C, Tsuji Y, Sakai Y, Sakurai K, Tomida S, Koike K, Fujishiro M. Transcriptome of sessile serrated adenoma\/polyps is associated with MSI-high colorectal cancer and decreased expression of CDX2. Cancer Med, 2022, 11(24):5066-5078. https:\/\/doi.org\/10.1002\/cam4.4810","DOI":"10.1002\/cam4.4810"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"[48] Cho H, Hashimoto T, Yoshida H, Taniguchi H, Ogawa R, Mori T, Hiraoka N, Saito Y, Sekine S. Reappraisal of the genetic heterogeneity of sessile serrated adenoma\/polyp. Histopathology, 2018, 73(4):672-680. https:\/\/doi.org\/10.1111\/his.13688","DOI":"10.1111\/his.13688"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"[49] Kim JH, Kim KJ, Rhee YY, Bae MJ, Cho NY, Lee HS, Kang GH. Gastric-type expression signature in serrated pathway-associated colorectal tumors. Hum Pathol, 2015, 46(5):643-656. https:\/\/doi.org\/10.1016\/j.humpath.2015.01.003","DOI":"10.1016\/j.humpath.2015.01.003"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"[50] Hiromoto T, Murakami T, Akazawa Y, Sasahara N, Saito T, Sakamoto N, Mitomi H, Nagahara A, Yao T. Immunohistochemical and genetic characteristics of a colorectal mucin-rich variant of traditional serrated adenoma. Histopathology, 2018, 73(3):444-453. https:\/\/doi.org\/10.1111\/his.13643","DOI":"10.1111\/his.13643"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"[51] Higuchi T, Sugihara K, Jass JR. Demographic and pathological characteristics of serrated polyps of colorectum. Histopathology, 2005, 47(1):32-40. https:\/\/doi.org\/10.1111\/j.1365-2559.2005.02180.x","DOI":"10.1111\/j.1365-2559.2005.02180.x"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"[52] Guo RJ, Funakoshi S, Lee HH, Kong J, Lynch JP. The intestine-specific transcription factor Cdx2 inhibits beta-catenin\/TCF transcriptional activity by disrupting the beta-catenin-TCF protein complex. Carcinogenesis, 2010, 31(2):159-66. https:\/\/doi.org\/10.1093\/carcin\/bgp213","DOI":"10.1093\/carcin\/bgp213"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"[53] Joo MK, Park JJ, Chun HJ. Impact of homeobox genes in gastrointestinal cancer. World J Gastroenterol, 2016, 22(37):8247-8256. https:\/\/doi.org\/10.3748\/wjg.v22.i37.8247","DOI":"10.3748\/wjg.v22.i37.8247"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"[54] Hinoi T, Loda M, Fearon ER. Silencing of CDX2 expression in colon cancer via a dominant repression pathway. J Biol Chem, 2003, 278(45):44608-44616. https:\/\/doi.org\/10.1074\/jbc.M307435200","DOI":"10.1074\/jbc.M307435200"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"[55] Ban S, Mitomi H, Horiguchi H, Sato H, Shimizu M. Adenocarcinoma arising in small sessile serrated adenoma\/polyp (SSA\/P) of the colon: clinicopathological study of eight lesions. Pathol Int, 2014, 64(3):123-132. https:\/\/doi.org\/10.1111\/pin.12147","DOI":"10.1111\/pin.12147"},{"key":"ref55","unstructured":"[56] Cansiz Ers\u00f6z C, Kiremitci S, Savas B, Ensari A. Differential diagnosis of traditional serrated adenomas and tubulovillous adenomas: a compartmental morphologic and immunohistochemical analysis. Acta Gastroenterol Belg, 2020, 83(4):549-556."},{"key":"ref56","unstructured":"[57] Per\u00e7inel S, Sava\u015f B, Ensari A, Kuzu I, Kuzu MA, Bekta\u015f M, Cetinkaya H, Kur\u015fun N. Mucins in the colorectal neoplastic spectrum with reference to conventional and serrated adenomas. Turk J Gastroenterol, 2007, 18(4):230-238."},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"[58] Tanaka Y, Eizuka M, Uesugi N, Kawasaki K, Yamano H, Suzuki H, Matsumoto T, Sugai T. Traditional serrated adenoma has two distinct genetic pathways for molecular tumorigenesis with potential neoplastic progression. J Gastroenterol, 2020, 55(9):846-857. https:\/\/doi.org\/10.1007\/s00535-020-01697-5\"","DOI":"10.1007\/s00535-020-01697-5"}],"container-title":["Romanian Journal of Morphology and Embryology"],"original-title":[],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T08:47:13Z","timestamp":1748594833000},"score":1,"resource":{"primary":{"URL":"https:\/\/rjme.ro\/archive\/66\/1\/9\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,15]]},"published-print":{"date-parts":[[2025,5,23]]}},"URL":"https:\/\/doi.org\/10.47162\/rjme.66.1.09","relation":{},"ISSN":["1220-0522","2066-8279"],"issn-type":[{"value":"1220-0522","type":"print"},{"value":"2066-8279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}